Overview

Early Treatment With Candesartan vs Placebo in Genetic Carriers of Dilated Cardiomyopathy (EARLY-GENE Trial)

Status:
Not yet recruiting

Trial end date:
2026-05-02

Target enrollment:

Participant gender:

Summary

Prospective, multicenter, randomized, placebo-controlled, double-blind clinical trial to evaluate safety and efficacy of candesartan in the prevention of the development of Dilated Cardiomyopathy (DCM) in genetic carriers of a DCM-causing variant without disease expression (asymptomatic)

Phase:

Phase 3

Details

Lead Sponsor:

Cristina Avendaño Solá

Treatments:

Candesartan